Cohance Lifesciences Appoints Abhimanyu Ojha as New CFO Effective Oct 12, 2026
Cohance Lifesciences Limited appointed Mr. Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026. The Board of Directors approved the appointment on October 9, 2026. Mr. Ojha has over 20 years of finance leadership experience in the pharmaceutical industry.
The appointment of a Chief Financial Officer is a significant management change that can impact the company's financial strategy and operations, warranting a medium impact.
The appointment of a new CFO with extensive experience is generally viewed positively as it can bring fresh perspectives and strengthen financial leadership.
Cohance Lifesciences Limited has announced the appointment of Mr. Abhimanyu Ojha as its new Chief Financial Officer (CFO) and Key Managerial Personnel. This significant decision was approved by the Board of Directors, based on the recommendation of its Nomination and Remuneration Committee, during a meeting held on Friday, 9 October 2026.
Mr. Ojha's appointment is effective from 12 October 2026. Alongside his appointment as CFO, the company has also updated its authorized Key Managerial Personnel for disclosures under Regulation 30(5) of the SEBI Listing Regulations, a change also effective from 12 October 2026. The policy for determining material events and information has been amended to reflect this.
Mr. Ojha brings over two decades of extensive experience in finance leadership roles within the multinational healthcare and pharmaceutical sectors. His prior experience includes serving as Global CFO & President Finance at Intas Pharmaceuticals and holding senior leadership positions at Viatris, Sun Pharmaceuticals, and Ranbaxy Laboratories. He possesses broad expertise in financial strategy, business partnering, corporate governance, mergers and acquisitions, treasury, tax, risk management, and operational excellence. The Board Meeting commenced at 7:45 PM IST and concluded at 8:00 PM IST on October 9, 2026.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under key management changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.